Valneva SE (VALN) Revenue & Revenue Breakdown
Valneva SE Revenue Highlights
Latest Revenue (Y)
$153.70M
Latest Revenue (Q)
$32.75M
Main Segment (Y)
IXIARO
Main Geography (Y)
UNITED STATES
Valneva SE Revenue by Period
Valneva SE Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $153.70M | -57.46% |
2022-12-31 | $361.30M | 3.80% |
2021-12-31 | $348.08M | 215.52% |
2020-12-31 | $110.32M | -12.58% |
2019-12-31 | $126.20M | 11.64% |
2018-12-31 | $113.03M | 7.35% |
2017-12-31 | $105.29M | 11.94% |
2016-12-31 | $94.06M | 20.04% |
2015-12-31 | $78.36M | 112.22% |
2014-12-31 | $36.92M | 21.28% |
2013-12-31 | $30.45M | 787.35% |
2012-12-31 | $3.43M | -66.57% |
2011-12-31 | $10.26M | 22.25% |
2010-12-31 | $8.39M | 171.16% |
2009-12-31 | $3.10M | -9.42% |
2008-12-31 | $3.42M | 294.69% |
2007-12-31 | $866.00K | -62.82% |
2006-12-31 | $2.33M | -22.65% |
2005-12-31 | $3.01M | - |
Valneva SE Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $32.75M | -21.83% |
2023-12-31 | $41.90M | 10.05% |
2023-09-30 | $38.07M | -5.38% |
2023-06-30 | $40.23M | 20.08% |
2023-03-31 | $33.51M | -69.92% |
2022-12-31 | $111.40M | -28.90% |
2022-09-30 | $156.68M | 119.51% |
2022-06-30 | $71.38M | 226.69% |
2022-03-31 | $21.85M | -92.15% |
2021-12-31 | $278.24M | 1145.13% |
2021-09-30 | $22.35M | -7.99% |
2021-06-30 | $24.29M | 4.61% |
2021-03-31 | $23.22M | -54.90% |
2020-12-31 | $51.47M | 370.46% |
2020-09-30 | $10.94M | -13.76% |
2020-06-30 | $12.69M | -63.98% |
2020-03-31 | $35.22M | -21.39% |
2019-12-31 | $44.80M | 66.65% |
2019-09-30 | $26.88M | 36.79% |
2019-06-30 | $19.65M | -43.61% |
2019-03-31 | $34.86M | 0.43% |
2018-12-31 | $34.71M | 79.25% |
2018-09-30 | $19.36M | -27.98% |
2018-06-30 | $26.88M | -16.20% |
2018-03-31 | $32.08M | 10.82% |
2017-12-31 | $28.95M | 28.76% |
2017-09-30 | $22.48M | -11.54% |
2017-06-30 | $25.42M | -10.65% |
2017-03-31 | $28.44M | 9.27% |
2016-12-31 | $26.03M | 41.51% |
2016-09-30 | $18.39M | -28.95% |
2016-06-30 | $25.89M | 9.02% |
2016-03-31 | $23.75M | 13.36% |
2015-12-31 | $20.95M | 3.68% |
2015-09-30 | $20.20M | 8.68% |
2015-06-30 | $18.59M | -0.11% |
2015-03-31 | $18.61M | 61.92% |
2014-12-31 | $11.49M | 3.81% |
2014-09-30 | $11.07M | 37.16% |
2014-06-30 | $8.07M | 28.55% |
2014-03-31 | $6.28M | -29.26% |
2013-12-31 | $8.88M | -35.79% |
2013-09-30 | $13.83M | 97.37% |
2013-06-30 | $7.00M | 850.47% |
2013-03-31 | $737.00K | -17.65% |
2012-12-31 | $895.00K | -13.28% |
2012-09-30 | $1.03M | - |
Valneva SE Revenue Breakdown
Valneva SE Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
DUKORAL | $29.77M | $17.34M | $2.40M |
IXIARO | $73.48M | $41.37M | $45.10M |
Third Party Products | $35.67M | $26.55M | - |
Others Products | $3.09M | - | - |
Lyme Candidate Vaccine | - | - | $14.30M |
COVID | - | - | $253.31M |
Latest
Valneva SE Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 |
---|---|---|
Other Europe | $9.34M | $6.25M |
Nordics | $12.70M | $8.56M |
GERMANY | $13.50M | $20.34M |
FRANCE | $5.87M | $2.63M |
CANADA | $28.19M | $18.90M |
UNITED STATES | $32.96M | $21.99M |
Rest Of World | $16.31M | $11.48M |
AUSTRIA | $14.58M | $13.75M |
Latest
Valneva SE Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
VALN | Valneva SE | $153.70M | $32.75M |
SAGE | Sage Therapeutics | $86.45M | $11.87M |
RVMD | Revolution Medicines | $11.58M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
INBX | Inhibrx Biosciences | $1.80M | - |
OPT | Opthea | $108.41K | $61.27K |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
RLYB | Rallybio | - | $299.00K |
CNTB | Connect Biopharma | - | - |
NCNA | NuCana | - | - |
TIL | Instil Bio | - | - |
MLYS | Mineralys Therapeutics | - | - |
THRD | Third Harmonic Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
EWTX | Edgewise Therapeutics | - | - |
SLS | SELLAS Life Sciences Group | - | - |
NUVB | Nuvation Bio | - | $727.00K |
TYRA | Tyra Biosciences | - | - |